Guangdong Provincial People's Hospital

This study is testing whether giving the drug lorlatinib before surgery or radiation helps people with stage III non-small cell lung cancer that has a specific genetic change (ALK fusion). About 48 participants will take lorlatinib for three cycles. Doctors will then check if the…

This study is looking at which treatment works better for people with higher-risk forms of two blood disorders called MDS and CMML. Researchers are comparing a two-drug combination (venetoclax plus HMAs) against just the HMAs drug alone. They're reviewing medical records of 224 p…

This study is testing a new three-drug combination given before surgery for early-stage triple-negative breast cancer (TNBC), an aggressive type. The goal is to see if adding two newer drugs (sintilimab and anlotinib) to standard chemotherapy can better shrink or eliminate the tu…

This study is testing whether adding two newer types of drugs (a PCSK9 inhibitor and a PD-1 inhibitor) to standard pre-surgery chemotherapy and radiation can better shrink tumors in people with a specific type of locally advanced rectal cancer. It will enroll about 30 patients to…

This study is testing whether adding a new immunotherapy drug called serplulimab to standard chemotherapy (FLOT) works better for people with stage III stomach cancer. The goal is to see if the combination helps more patients achieve a 'pathological complete response,' meaning no…

This study is testing if adding the supplement N-acetylcysteine (NAC) helps people with severe OCD that hasn't improved with standard medications. Researchers will use brain scans on 90 participants to see if NAC works by changing levels of a brain chemical called glutamate. The …

This study is testing whether artificial intelligence (AI) can predict a future heart attack by analyzing a person's past electrocardiogram (ECG) scans, even if those scans were originally read as 'normal'. Researchers will use data from 150,000 patients to see if the AI can find…

This study is testing whether a medication called Crisugabalin can safely reduce chronic pain in people with Parkinson's disease. Researchers will compare 166 participants taking either Crisugabalin or a placebo (inactive pill) for 12 weeks to see which group experiences better p…

This study aims to better understand how heart and lung function relate to future heart problems in Chinese patients with various heart conditions. Researchers will follow 200,000 participants for five years, using exercise tests to measure heart and lung performance. The goal is…